Semnur Pharmaceuticals, Inc.

IN THE PRESS

Press Releases

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali

November 7, 2024

·

13 min read

Press Releases

Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

October 28, 2024

·

14 min read

Press Releases

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion

October 16, 2024

·

13 min read

Press Releases

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value of Semnur of $2.5 Billion

September 3, 2024

·

17 min read

Business

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination

July 3, 2024

·

20 min read

Drug Development

Semnur Pharma Begins Pivotal Phase III Trial For SP-102 in Patients With Lumbar Radicular Pain/Sciatica

January 7, 2018

·

6 min read

Drug Development

Semnur Announces Successful Phase I/II Trial In Patients With Radicular Pain For Its Lead Product, SP-102

June 26, 2017

·

6 min read

Deals

Sorrento’s Subsidiary Scintilla Pharma Snapped Up Semnur for $200 Million

August 16, 2016

·

6 min read

Biotech Bay

Semnur Files SEC Form D, Notice Of Exempt Offering Of Securities

September 26, 2014

·

1 min read

Biotech Bay

Back Pain Drug Developer Semnur Raises $6 Million

September 26, 2014

·

1 min read

AWARDS

JOBS